FierceBiotech 8 janv. 2026 WEP Clinical grabs European CRO Siron Clinical, broadening global capabilities
FierceBiotech 8 janv. 2026 Lilly links up with InduPro in next-gen cancer treatment deal worth up to $950M
FierceBiotech 7 janv. 2026 Pulmocide calls curtains on phase 3 antifungal trial over low response, higher mortality rate
FierceBiotech 7 janv. 2026 Gilead study finds HIV can evolve to resist lenacapavir, but doing so hampers the virus’ replication
FierceBiotech 7 janv. 2026 Staar Surgical's takeover saga ends as shareholder revolt stops Alcon’s attempted merger deal
FierceBiotech 7 janv. 2026 Fierce Biotech Fundraising Tracker '26: Soley sees $200M series C; Rakuten rakes in $100M
FierceBiotech 7 janv. 2026 Hutchmed heats up autoimmune race with phase 3 win, teeing up China filing
FierceBiotech 7 janv. 2026 GSK's 'functional cure' for hep B proves worth in phase 3 trials setting up approval push
FierceBiotech 6 janv. 2026 Arrowhead takes aim at obesity market with early data on dual gene silencing assets
FierceBiotech 6 janv. 2026 In Structure licensing deal, Roche commits $100M to shore up GLP-1 position
FierceBiotech 6 janv. 2026 Amgen stitches new acquisition worth up to $840M for UK biotech and its cancer programs
FierceBiotech 6 janv. 2026 Bright Minds shines with phase 2 win for anti-seizure serotonin receptor activator
FierceBiotech 6 janv. 2026 Boehringer continues kidney disease dealmaking run with $120M Variant Bio pact